Philippines Drug Prices Still High Year After Cheaper-Drugs Law Passed
This article was originally published in PharmAsia News
Executive SummaryJust over a year ago, The Philippines enacted a "cheaper medicines" law intended to drive down the cost of drugs. But more than a year later, many of those drugs are selling at the same prices they sold at a year ago, leading one senator to launch an inquiry into why the Cheaper Medicines Act was not working as intended. Health authorities respond that the country is among the nations with the most expensive pharmaceuticals, two to 10 times higher than some of the same brands in other countries. (Click here for more
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.